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Abstract: Prostaglandins have been attractive targets in total synthesis for over 50 years, resulting
in the development of new synthetic strategies and methodologies that have served the broader
chemical community. However, these molecules are not just of academic interest, a number of
prostaglandin analogues are used in the clinic, and some are even on the WHO list of essential
medicines. In this personal account, we describe our own approach to the family of
prostaglandins, which centers around the synthesis of a key enal intermediate, formed from the
l-proline catalysed dimerization of succinaldehyde. We highlight the discovery and further
optimization of this key reaction, its scale up, and subsequent application to a range of
prostaglandins.
Keywords: Prostaglandins, Total Synthesis, Organocatalysis, Aldol Reaction, Asymmetric
Synthesis
1. Introduction
Prostaglandins (PGs) are a unique family of diverse eicosanoid
lipid mediators that act as local hormones within the body.
When required, they are synthesised on demand and act either
at (autocrine) or adjacent to (paracrine) their site of
synthesis.[1] They are implicated in numerous biological
processes but are key players in generating the inflammatory
response associated with tissue damage.[2] Pioneering research
into prostaglandins began in the 1930s with notable contribu-
tions from both von Euler and Goldblatt,[3] but it was not
until the late 1950s that their chemical structures began to be
elucidated, thanks to the seminal work of Bergström and
Samuelsson.[4]
1.1. Biological Significance and Medicinal Use of the
Prostaglandins
Since their discovery and subsequent structural elucidation,
considerable efforts in both industry and academia have
focused on understanding the diverse range of biological
functions that prostaglandins regulate. These functions include
pain signaling, inflammation, fever, smooth muscle contrac-
tion and relaxation, and modulation of platelet
aggregation.[1,2,5] Due to their biological significance, prosta-
glandins and their analogues have emerged as important
molecules in the treatment of a range of medical conditions.
For example, the compounds latanoprost, travoprost, and
bimatoprost are PGF2α analogues used to treat glaucoma, a
cause of irreversible blindness.[6] Development of prostaglandin
analogues is still ongoing, as evidenced by the recent approval
of tafluprost and latanoprostene bunod, both for the treatment
of ocular hypertension,[7] as well as a number of PGF2α
analogues for the reduction of adipose tissue around the eyes.[8]
2. Previous syntheses of PGF2α
The complex structure of prostaglandins, together with their
broad spectrum of biological activity fueled intense research
activity from the synthetic community, comparable to that
generated from β-lactam antibiotics and steroids. Woodward,[9]
Corey,[10] Stork,[11] Noyori,[12] Danishefsky,[13] and many others
contributed ingenious strategies and developed new method-
ologies of general utility in the construction of these complex
molecules.[14] Corey completed the first total synthesis of
PGF2α[10] by exploiting the stereocontrol from a Diels Alder
reaction to ultimately create a bicyclic lactone (subsequently
dubbed the “Corey lactone”) housing the functionality and
stereochemistry required to access not just PGF2α but also a
whole range of prostaglandins and their analogues (Scheme 1).
In the fifty years since the Corey lactone was first reported,
a number of impressive strategies have emerged to prepare this
crucial intermediate.[10,14,15] Most notably, a dramatic gram-
scale synthesis of the lactone was recently reported by Hayashi
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production in any medium, provided the original work is properly
cited. Scheme 1. The original Corey lactone synthesis from cyclopentadiene.[10]
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in a one-pot sequence in only 152 minutes.[16] Hayashi has
also successfully synthesised several prostanoids through the
use of similar organocatalytic methodology.[17]
2.1. Stork’s Radical Trapping Approach
It is relevant to discuss Stork’s synthesis of PGF2α since our
own route was partly inspired by his elegant use of a radical
cyclisation/trapping sequence (Scheme 2).[11] In Stork’s case,
α-iodoacetal 1 (accessed in 7 steps from cyclopentadiene) was
subjected to homolytic cleavage of the C  I bond using his
catalytic tin hydride method.[18] The radical generated then
underwent Ueno-Stork cyclisation[19] to give bicyclic acetal 2
and produce an intermediary radical that trapped the Stork-
Ganem reagent[20] exclusively on the exo face of the bicycle,
creating two new C  C bonds and installing the ω-sidechain of
PGF2α in one exquisitely orchestrated sequence.
Following thermal rearrangement of α-silyl ketone 3 to the
trimethylsilyl enol ether and subsequent Saequsa-Ito oxidation
to enone 4, Stork quickly finished the synthesis of PGF2α in
three further steps, furnishing the natural product in 13 total
steps from cyclopentadiene.
The high stereocontrol observed in the trapping of radical
2 is due to the convex shape of the bicyclic intermediate,
which favours attack from the more exposed exo face – a
strategy we were keen to exploit in our own total synthesis of
PGF2α.
3. Retrosynthetic Analysis of PGF2α
We considered developing an alternative approach to PGF2α
that focused on synthesising a strategically functionalized
bicycle that incorporated both the cyclopentane core of the
natural product and two functional group handles at an
appropriate oxidation level to facilitate the introduction of the
sidechains.[21]
In line with other syntheses of PGF2α our retrosynthesis
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Scheme 2. Stork’s radical trapping approach towards PGF2α.[11]
P e r s o n a l A c c o u n t TH E CH EM I C A L R E CORD
Chem. Rec. 2020, 20, 1–13 © 2020 The Authors. Published by The Chemical Society of Japan & Wiley-VCH Verlag GmbH & Co. KGaA 3
began by disconnecting the C5/C6 Z-alkene with a Wittig
reaction to give hemiacetal 5 (Scheme 3).[9,11,13,14] From this
point our retrosynthesis departed all previous routes. We
considered functional group interconversion (FGI) of the C11
alcohol to an electron withdrawing group such as an aldehyde.
This would allow for disconnection of the ω-sidechain by a
conjugate addition process, the stereochemistry of which
should be controlled by the convex shape of bicyclic enal 6, as
discussed above. Key enal 6 could then be disconnected back
to hemiacetal 7/trialdehyde 8 through an aldol condensation
and then further back to succinaldehyde through an additional
aldol reaction. It was envisaged that the stereodetermining step
of this process could be carried out by an l-proline catalysed
aldol dimerization of succinaldehyde.[21]
In this account we chart the many difficulties we faced in
the development of this synthesis, the most challenging of
which was the l-proline catalysed dimerization of succinalde-
hyde, and how eventually we were able to perform this
challenging reaction on decagram scale giving enal 6 in 99 :1
e.r. from extremely simple building blocks.
4. l-Proline Catalysed Aldol Reaction of
Succinaldehyde
4.1. Synthesis of Succinaldehyde by Neutral Hydrolysis of
2,5-Dimethoxytetrahydrofuran
The first challenge we faced was the preparation of succinalde-
hyde. This sensitive material has been prepared by acid
hydrolysis of 2,5-diethoxytetrahydrofuran but we found that
this method did not provide material of sufficient purity.[22]
We were instead attracted to a method by Smith who reported
the hydrolysis of 2,5-dimethoxytetrahydrofuran in hot D2O
under neutral conditions.[23] Smith used the resulting solution
of succinaldehyde directly, without further purification;
however, we needed to purify it in order to avoid the
hydrolysis by-products from interfering in our subsequent
aldol reaction.
We therefore heated 2,5-dimethoxytetrahydrofuran in
water and after extraction of the reaction mixture, we observed
near complete consumption of the acetal and considerable
amounts of succinaldehyde, together with some partially
hydrolysed material.
We were able to scale-up the hydrolysis to provide multi-
gram quantities of succinaldehyde (Scheme 4, A). Practically,
this involved heating 2,5-dimethoxytetrahydrofuran (140 mL)
in water (420 mL) at 75 °C for 4 h, followed by removal of
methanol and water by distillation at 120 °C for 4 h (400 mL
of distillate was collected). After numerous extractions with
dichloromethane (CH2Cl2) (70×25 mL), MgSO4 drying, and
concentration of the extracts in 250 ml batches we obtained
succinaldehyde of high purity but in variable yields.
Succinaldehyde produced in this way was obtained as a
pale-yellow liquid and could be distilled under reduced
pressure, but it was prone to polymerisation in just a few
hours. It was either used directly after distillation or was stored
as a solution in CH2Cl2 at   20 °C and used within 48 h. This
procedure provided sufficient quantities of succinaldehyde for
our initial investigations but the tedious and numerous
extractions, and concentration of the resultant extracts in
batches pushed us to develop a more effective protocol for
large scale synthesis. Instead of trying to extract the water
soluble succinaldehyde into an organic solvent we decided to
focus on azeotropic removal of the water (Scheme 4, B). We
found that after distilling off most of the water and methanol
Scheme 3. Our retrosynthetic analysis of prostaglandin PGF2α.[21]
Scheme 4. Synthesis of succinaldehyde by the neutral hydrolysis of 2,5-
dimethoxytetrahydrofuran.
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(MeOH), addition of 2-methyltetrahydrofuran (2-MeTHF)
allowed for azeotropic removal of water (Dean-Stark, 95 °C,
8 h) and gave succinaldehyde as a solution in 2-MeTHF. Both
THF, and more importantly 2-MeTHF, turned out to be
suitable solvents for the subsequent aldol reaction.
However, isolation of succinaldehyde as a solution in
2-MeTHF made subsequent aldol reaction optimization more
challenging as we were constrained to this solvent. Therefore,
we sought to develop an effective azeotropic procedure that
would facilitate isolation of neat succinaldehyde (Scheme 4,
C). In this respect, our latest procedure – which can be
performed on a 50–200 g scale using standard lab glassware or
a jacketed reactor vessel system – allowed us to isolate
succinaldehyde in 60–70% yield as a neat liquid. Following
initial hydrolysis of 2,5-dimethoxytetrahydrofuran (90 °C, 2 h)
and subsequent distillation to remove most of the water and
MeOH, azeotropic removal of the remaining water was
performed with toluene under reduced pressure. Finally,
distillation of the crude material under reduced pressure
delivered the desired succinaldehyde for use in the subsequent
l-proline catalysed dimerization.
4.2. Initial Investigations of the l-Proline Catalysed Aldol
Reaction of Succinaldehyde
With a reliable route to succinaldehyde in hand, we
investigated the subsequent l-proline catalysed aldol reaction
in both DMSO and THF at room temperature. However, no
desired enal product 6 was formed in either case. A broad
range of l-proline-like catalysts were tested in a range of
solvents but in no case was any product even detected.
The challenge of the reaction was perhaps not surprising as
the product from the first aldol is the highly reactive
trialdehyde 8, which can undergo a myriad of unproductive
reaction pathways (Scheme 5). We wanted trialdehyde 8 to
form hemiacetal 7 before ultimately undergoing an aldol
condensation to give enal 6. However, it could equally form
less hindered hemiacetal 12, undergo elimination to give enal
11 or even perform further aldol reactions with succinaldehyde
to give oligomeric mixtures. Indeed, all we saw were gummy
reaction mixtures indicative of oligomer formation. At this
point we could have given up on our quest, but instead we
decided to break down the problem. We asked ourselves,
which of the two steps was problematic: the first intermolecu-
lar aldol reaction or the second intramolecular aldol reaction
followed by dehydration? Typically, intermolecular reactions
are more difficult than intramolecular reactions but here the
opposite was true.
To model the first step of our process, we studied the
l-proline catalysed aldol reaction of aldehyde 15 bearing a
methyl ester in the 4-position instead of another aldehyde
(Scheme 6). We thought that the aldol product 16 from such
a reaction would be more stable and less likely to undergo
further side reactions.
The l-proline catalysed dimerization of aldehyde 15 led to
a 61% yield of aldol product 16 with a diastereomeric ratio of
3.6 :1.This successfully showed that the first aldol step of our
process should work well and tolerate a carbonyl group in the
4-position.
In order to model the second step, we chose to investigate
dialdehyde 18 as it contains a 1,6-dialdehyde with the correct
relative stereochemistry but on a more stable lactone, rather
than a hemiacetal (Scheme 7). Dialdehyde 18 was prepared by
Scheme 5. Possible reaction pathways in the l-proline catalysed aldol
reaction of succinaldehyde.[21]
Scheme 6.Model study for the intermolecular aldol reaction of a related
aldehyde.
Scheme 7.Model studies to investigate the intramolecular aldol condensa-
tion.
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ozonolysis of known cyclohexene 17 and used without
purification in the subsequent aldol condensation.
Addition of l-proline to dialdehyde 18 in THF only gave a
5% yield of lactone product 19 (over 2 steps), quickly
demonstrating that it was a poor catalyst for the second step of
our process. This result surprised us initially, as we had
expected the intramolecular aldol to be much easier than the
intermolecular aldol. However, a review of the literature
highlighted the sensitivity of this intramolecular step to subtle
structural changes. For example, Afonso showed that the
nature of the 1,6-dialdehyde bridge can make all the difference
between success and failure of this step: the imide bridge of 20
gave the desired enal product 21 in good yield, but the ketal
bridge in 22 essentially failed (Scheme 8).[24]
In Corey’s synthesis of gibberellic acid, he used dibenzy-
lammonium trifluoroacetate ([Bn2NH2][OCOCF3]) to effect
the aldol condensation of a 1,6-dialdehyde to an enal.[25] We
therefore explored the use of this catalyst and were delighted to
find that in our model system, lactone 19 was obtained in
51% yield over 2 steps (Scheme 7).
This result indicated that we needed a combination of
catalysts to be successful: l-proline for the first step and then
dibenzylammonium trifluoroacetate for the second step.
However, could each catalyst work independently, performing
their desired role without interference from each other? For
example, dibenzylammonium trifluoroacetate should not cata-
lyse the first aldol, otherwise we would get material with low
e.r., and it must not prevent the first catalyst from performing
its role, otherwise we would get low yields of product. These
issues were explored next.
4.3. The l-Proline Catalysed Aldol Reaction of
Succinaldehyde Revisited
The aldol reaction cascade of succinaldehyde was therefore
tested with a combination of l-proline and [Bn2NH2]
[OCOCF3] (Table 1). Unfortunately, when the two catalysts
were added together no product was obtained (entry 1). This
was perplexing, as we knew from our model studies that
l-proline could catalyse the first aldol reaction and [Bn2NH2]
[OCOCF3] could catalyse the second. We therefore tried
adding the catalysts sequentially: l-proline was added first and
then after an arbitrary time of 4 h, [Bn2NH2][OCOCF3] was
added. Finally, we were successful, and the product was
obtained in 7% yield (entry 2). Crucially, the e.r. was found
to be 99 :1 by chiral GC analysis, showing that [Bn2NH2]
[OCOCF3] was not promoting the first aldol reaction; this was
being done exclusively by l-proline. Clearly the timing of the
addition of the second catalyst was critical, if it was added too
early it interfered with the l-proline catalysed aldol and if it
was added too late the succinaldehyde simply oligomerised,
and so we spent some time investigating this facet of the
reaction. The optimum time to add the second catalyst was
found to peak at around 10 h after addition of l-proline
(entry 4), which gave enal 6 in 13% yield.
The reaction was subsequently scaled up (entry 6) and,
after formation of methyl acetal 24 (MeOH, Amberlyst 15,
MgSO4) from crude enal 6, we were able to successfully isolate
15 g (13% yield) of desired product in 99 :1 e.r. for use in our
total synthesis. However, it was still particularly challenging to
isolate and purify the desired product from the oligomeric
side-products.
Scheme 8. Afonso’s intramolecular aldol condensations.[24]
Table 1. Initial optimization of the synthesis of enal 6.[a][21]
Entry t [h] Yield [%][b][c]
1 0 <1
2 4 7
3 6 11
4 10 13
5 24 13
6[d] 20 13
[a] Reaction conditions (unless otherwise stated): Succinaldehyde
(2.32 mmol), l-proline (2 mol%), THF (2 m), RT, t [h]; then:
[Bn2NH2][OCOCF3] (2 mol%), THF (1 m), RT, 14 h. [b] Yields
determined by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene
as an internal standard; results are an average of five experiments. [c]
The NMR yields given here are lower than originally reported as
relaxation delay was not applied during initial optimization studies;
[d] 109.5 g succinaldehyde (1.272 mol) was used; isolated yield
determined after formation of methyl acetal 24.
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5. The Total Synthesis of prostaglandin PGF2α
5.1. Development of a 1,4-conjugate Addition
Having achieved a scalable synthesis of enal 6 we embarked on
the total synthesis of PGF2α as described in our proposed route
(Scheme 9).
Following protection of enal 6 as its methyl acetal 24, the
next step required 1,4-conjugate addition of an alkenyl
nucleophile to the α,β-unsaturated aldehyde of 24. Initially,
we focused our efforts on using an organocuprate, a process
which had precedent in previous prostanoid syntheses.[26] We
chose to use a mixed cuprate with a non-transferable ligand to
avoid wasting the valuable alkenyl sidechain. In this respect,
we were attracted to Lipshutz’s higher order cyanocuprates,
which can transfer a vinyl group in the presence of a thienyl
group.[27] Thus, we prepared mixed cuprate 28 then reacted it
with 24 to give aldehyde 25 as a mixture of two
diastereoisomers at the C11 aldehyde centre (Scheme 10),
showing that conjugate addition had occurred with complete
facial selectivity, as expected based on Stork’s PGF2α synthesis
(Section 2.1.)
5.2. Investigations into an Oxidative Cleavage Reaction
With the ω-sidechain installed, the next challenge was to
perform oxidative cleavage of the aldehyde, which proved to
be more difficult than expected. We initially attempted a
copper-catalysed oxidative cleavage process using copper
acetate (CuOAc)2 and 1,4-Diazabicyclo[2.2.2]octane (DAB-
CO) under O2,[28] but in our case the aldehyde of 25 was
consumed very slowly, with no identifiable products charac-
terised.
The failure of the copper-catalysed oxidative cleavage
reaction led us to investigate an alternative approach involving
Rubottom oxidation (Scheme 11). Following 1,4-conjugate
addition of mixed cuprate 28 and trapping of the enolate with
trimethylsilyl chloride (TMSCl), silyl enol ether 29 was
epoxidised with m-CPBA. However, instead of giving
α-hydroxyaldehyde 31 as expected, we obtained mixed acetal
30. A related reaction had previously been reported by
Pinnick.[29]
Cleavage of this mixed acetal with TBAF then gave desired
α-hydroxyaldehyde 31 in 39% over 2 steps. Subsequent
reduction with NaBH4 followed by oxidative cleavage with
NaIO4 gave ketone 26, which was stereoselectively reduced
with NaBH4 from the less hindered exo face, giving alcohol
27. While this was a lengthy and rather inefficient sequence,
one positive outcome was the observation that NaBH4 could
Scheme 9. Initially proposed route to PGF2α from enal 6.
Scheme 10. Reaction of mixed cuprate 28 with the α,β-unsaturated aldehyde
of 24.
Scheme 11. Oxidative cleavage of silyl enol ether 29 by Rubottom oxidation
followed by Malaprade reaction.
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provide us with the required C11 alcohol as a single
diastereoisomer from ketone 26.
This result inspired us to investigate an alternative protocol
where we considered using ozonolysis to cleave the more
electron-rich silyl enol ether of 29 in the presence of the
disubstituted alkene. It was clearly going to be tricky to stop
the addition of ozone once all the silyl enol ether had been
consumed, but fortunately there are a wide variety of dyes
available to assist. A dye can be selected which is less electron-
rich than the alkene you want to cleave but more electron-rich
than the one you want to keep.[30] We tested several dyes and
found that Sudan III was the most successful dye as its colour
began to fade just as consumption of silyl enol ether 29 was
nearly complete. This dye was used as a guide, with careful
thin-layer chromatographic (TLC) monitoring, to decide when
to terminate ozonolysis. At the end of the reaction, nitrogen
was bubbled through and the mixture treated with NaBH4,
which first cleaved the ozonides and then stereoselectively
reduced the ketone that was formed.
In the optimized procedure (Scheme 12): 1,4-conjugate
addition of mixed cuprate 28 with methyl acetal 24, followed
by trapping of the resultant enolate with TMSCl gave silyl
enol ether 29, which after work-up, underwent chemoselective
ozonolysis of the more electron-rich silyl enol ether to give,
after NaBH4 reduction, alcohol 27 on gram-scale.
5.3. Completion of the Synthesis of PGF2α
Removal of the TBS group and concomitant hydrolysis of the
methyl acetal in 27 was achieved using conditions described by
Stork (Scheme 13).[11] Triol 5 was found to be somewhat
unstable and so we carried out the Wittig reaction immedi-
ately. Phosphonium salt 32 was deprotonated using potassium
tert-butoxide (KOt-Bu) in THF and reacted with hemiacetal
5.[31] The reaction proceeded cleanly and PGF2α was isolated in
57% yield over 2 steps on 157 mg scale, or 47% yield over on
2 steps on 1.9 g scale.
In summary, we have developed a short (7 step) synthesis
of prostaglandin PGF2α from inexpensive and commercially
available 2,5-dimethoxytetrahydrofuran. The key step, an
organocatalytic dimerization of succinaldehyde, proved to be
exceptionally challenging but by breaking it down into its
constituent parts we were able to discover that two different
catalysts were required: l-proline to perform the first aldol
reaction and [Bn2NH2][OCOCF3] to induce the intramolecu-
lar aldol condensation. This gave the desired enal 6 in high e.r.
and fully primed with suitable functionality to directly
introduce the remaining sidechains. We quickly recognised
that bicyclic enal 6, like the Corey lactone, was an ideal
building block not just for PGF2α but for the whole
prostaglandin family. However, in order to realize this vision,
there was still an issue we needed to address. The Achilles heel
of the synthesis was the low yield and difficult purification
required in the aldol dimerization of succinaldehyde. As such,
considerable effort was devoted to developing a more efficient
aldol reaction.
6. Re-Optimization of the Organocatalysed Aldol
to the Key Enal
In order to improve our process, we started a further re-
optimization campaign, re-evaluating both aldol reaction steps
in the enal synthesis.[32]
Initial re-optimization studies (Table 2) demonstrated a
slight increase in yield from standard conditions (14%,
entry 1) by switching the solvent from THF to acetonitrile
(MeCN) (16%, entry 2), and a further increase by diluting the
concentration of the first aldol step (19%, entry 3). However,
at this stage we observed complications during purification of
enal 6, where a drop in isolated yield was observed (19%
NMR yield !9% isolated yield) due to the formation of
Scheme 12. Oxidative cleavage of silyl enol ether 29 by selective
ozonolysis.[21]
Scheme 13. Completion of the synthesis of PGF2α.[21]
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undesired hemiaminal 33, which resulted from condensation
of [Bn2NH2][OCOCF3] with enal 6 during silica gel
chromatography. We therefore screened alternative second
catalysts and found that thiomorpholinium trifluoroacetate ([S
(CH2)4NH2][OCOCF3]) was effective, providing enal 6 in
both a 20% NMR and isolated yield (entry 4). We were also
able to cut the reaction time for the second step from 24 hours
to 2 hours by heating the reaction mixture at 65 °C for 2 h, an
alteration which also improved the yield to 23% (entry 5). At
this point, we conducted an extended solvent screen again
where we observed that ethyl acetate (EtOAc) gave a visually
cleaner reaction profile (less oligomerisation) with a yield of
21% (cf. 23% for MeCN) and 12% residual succinaldehyde
(cf. 6% for MeCN) (entry 6). Finally, further assessment of
concentration and time revealed that by using an initial
concentration of 0.75 m for the first aldol and extending the
reaction time from 24 to 40 h, followed by dilution of the
reaction to 0.20 m for the second aldol and heating to 65 °C
for 2 h, gave an NMR yield of 33% with an isolated yield of
31% on a 0.5 g scale (entry 8). Graphically, the reaction has
been presented in Figure 1.
Work-up and purification of the reaction had always been
challenging due to the water-soluble nature of enal 6 and the
large amount of oligomers present. This often-meant multiple
extractions of the aqueous layer were needed to isolate enal 6.
However, a recent report highlighting the beneficial effects of
using Na2SO4 to “salt-out” water-soluble compounds
Table 2. Re-optimization of the synthesis of enal 6.[a][32]
Entry Solvent Cat. X T [°C] t [h] Conc. 1 [m] Conc. 2 [m] Yield [%][b] Residual Succinaldehyde [%][b]
1 THF A RT 14 2.0 1.0 14 –
2 MeCN A RT 20 2.0 1.0 16 –
3 MeCN A [c] RT 24 1.0 1.0 19 (9) –
4 MeCN B[c] RT 24 1.0 1.0 20 (20) –
5 MeCN B 65 2 2.0 2.0 23 6
6 EtOAc B 65 2 2.0 2.0 21 12
7 EtOAc B 65 2 0.5 0.5 28 19
8[d] EtOAc B 65 2 0.75 0.2 33 (31) 17
9[d][e] EtOAc B 65 2 0.75 0.35 32 (29) 19
[a] Reaction conditions (unless otherwise stated): Succinaldehyde (5.81 mmol), l-proline (2 mol%), solvent (X m), RT; then: 2nd catalyst
(2 mol%), [b] Yields determined by 1H NMR spectroscopy using 1,3,5-trimethoxybenzene as an internal standard (isolated yields in
parentheses). [c] 5 mol% of the 2nd catalyst was used. [d] 40 h reaction time for 1st step. [e] 50 g succinaldehyde (581 mmol) was used.
Figure 1. Image A represents the reaction immediately after the addition of
l-proline. Image B shows the reaction after 40 h at RT with l-proline, and
C shows the reaction at 65 °C, immediately after the addition of second
catalyst ([S(CH2)4NH2][OCOCF3]). The reaction ultimately turns a deep
purple colour (image D) that is likely due to the formation of oligomeric
material. The KMnO4 stained TLC of the reaction mixture before work-up
is shown in image E, where: the upper spot is residual succinaldehyde 9, the
middle spot is product enal 6, and the baseline spot is oligomeric material
(O.M.).
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prompted us to reinvestigate aqueous work-ups.[33] Using this
strategy, full recovery of enal 6 could be effected with just 3×
ethyl acetate extractions of the reaction mixture from an
aqueous solution of Na2SO4 (17% w/w). The crude material
was then purified by column chromatography using pre-
treated wet silica, which was found to retain any residual
succinaldehyde and oligomeric material. Ultimately, the
process could be scaled up 100× from 0.5 g (5.81 mmol) to
50 g (581 mmol) of succinaldehyde with minimal drop in
yield: 31% (0.14 g enal 6) on 0.5 g scale and 29% (12.8 g
enal 6) on 50 g scale (entry 9).[32]
6.1. Application of the Key Enal Towards the Total
Synthesis of Prostaglandins
In order to further establish our key enal 6 as a viable building
block for the total synthesis of prostaglandins, we initially
targeted the antiglaucoma drugs, bimatoprost and
latanoprost.[34] This extension of our methodology to prosta-
glandin-based pharmaceutically-relevant compounds allowed
us to demonstrate expedient access to life-changing medicines
in short step count – 7 or 8 for bimatoprost and latanoprost,
respectively – vs. 17 or 19 via the Corey lactone.[35,36]
The hemiacetal of enal 6 could either be converted to its
methyl acetal 24 (as a mixture of diastereoisomers) or to
lactone 19 using a Stahl oxidation.[37] The advantage of the
latter approach was that lactone 19 could be recrystallised to
>99 :1 e.r. and carried through a synthesis as a single
diastereomer, simplifying the subsequent steps (Scheme 14).
From enantioenriched lactone 19, both bimatoprost and
latanoprost could be synthesised in 5–6 steps with high overall
yields of 30–42% (Scheme 15).[34]
We were also able to apply our strategy to the synthesis of
the veterinary drug Alfaprostol,[38] where we utilized an
underexplored but powerful 1,4-conjugate addition of an
alkyne to introduce the lower ω-sidechain (Scheme 16).
Although alkynes are often used as non-transferable groups in
mixed organocuprates,[39] the addition of copper acetylides to
enals can be effected by using trimethylsilyl iodide (TMSI) as
an activator.[40] This approach greatly simplified both the 1,4-
addition and the subsequent ozonolysis: the former due to a
more facile generation of the copper acetylide compared to the
time-consuming mixed cyanocuprate, and the latter due to a
lack of competing ozonolysis of the lower ω-sidechain. The
total synthesis of Alfaprostol was subsequently completed in
only 8 steps from enal 6.[38]
Recognizing that we could use this approach to our
advantage, we also targeted an alternative synthesis of PGF2α,
where we would not have competing ozonolysis of the lower
sidechain or have to synthesis the mixed organocuprate.[38]
Alkyne 36 was subsequently prepared using the methodology
described above and following TBAF deprotection, the
resultant propargylic alcohol 37 was subsequently converted to
the (E)-crotyl alcohol by Chan reduction[41] (Scheme 17).
The total synthesis of PGF2α was completed in two further
steps from alcohol 37, and in only 8 steps total from enal 6.
Scheme 14. Differential protecting group strategies for enal 6.[34]
Scheme 15. Total syntheses of both latanoprost and bimatoprost from a
common lactone intermediate 19.[34]
Scheme 16. Alkyne 1,4-conjugate addition strategy for introducing the lower
ω-sidechain of Alfaprostol.[38]
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7. Summary and Outlook
In summary, we have developed a simple-yet-complex organo-
catalysed aldol dimerization of succinaldehyde that delivers
enal 6 in 29% yield, 99 : 1 e.r., and on decagram scale.[32] We
have utilized this key intermediate in the total synthesis of a
wide range of medicinally relevant prostaglandins, and in
almost half the number of steps previously reported.[21,32,34,38]
We have also been able to demonstrate the versatility of
enal 6 by successfully applying it to the total synthesis of stable
prostacyclin and thromboxane analogues,[42] again in consid-
erably fewer steps. Like the Corey lactone, our enal 6 possesses
the functionality and stereochemistry required to access a
broad range of prostanoid-based natural products. This has
enabled us to realize our vision of a universal approach to the
total synthesis of the whole prostanoid family. The brevity of
the synthesis facilitates analogues to be easily made and tested
for biological activity. Indeed, the bicyclic enal 6 is an ideal
building block not just for the cost-effective synthesis of the
whole family of prostanoids, but for also exploring chemical
space around the ubiquitous five-membered carbocyclic ring
motif, where other biologically active molecules remain to be
discovered.[43]
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